*Rei Yokoyama1,2, Yukio Ago2, Hisato Igarashi1, Momoko Higuchi1, Masato Tanuma1, Yuto Shimazaki1, Kaoru Seiriki1, Misuzu Hayashida1, Shun Yamaguchi3,4, Hirokazu Tanaka5, Takanobu Nakazawa6, Kenji Hashimoto7, Atsushi Kasai1,8, Hitoshi Hashimoto1,9,10,11,12
(1. Lab. Mol. Neuropharmacol., Grad. Sch. Pharmaceut. Sci., Osaka Univ., Osaka, Japan, 2. Dept. Cell. Mol. Pharmacol., Grad. Sch. Biomed. Health Sci., Hiroshima Univ., Hiroshima, Japan, 3. Dept. Morph. Neurosci., Grad. Sch. Med., Gifu Univ., Gifu, Japan, 4. Ctr. One Med. Innov. Transl. Res., Inst. Adv. Study, Gifu Univ., Gifu, Japan, 5. Fac. Info. Technol., Tokyo City Univ., Tokyo, Japan, 6. Dept. Biosci., Tokyo Univ. Agri., Tokyo, Japan, 7. Div. Clin. Neurosci., Chiba Univ. Ctr. Forensic. Mental Hlth., Chiba, Japan, 8. Sys. Brain Sci. Project, Drug Innov. Ctr., Grad. Sch. Pharmaceut. Sci., Osaka Univ., Osaka, Japan, 9. Mol. Res. Ctr. Children’s Mental Dev., United Grad. Sch. Child Dev., Osaka Univ., Osaka, Japan, 10. Inst. Datability Sci., Osaka Univ., Osaka, Japan, 11. Inst. Open Transdiscip. Res. Initiatives, Osaka Univ., Osaka, Japan, 12. Dep. Mol. Pharmaceut. Sci., Grad. Sch. Med., Osaka Univ., Osaka, Japan)
キーワード:Depression , Ketamine, (R)-ketamine, Social isolation
要旨・抄録、PDFの閲覧には参加者用アカウントでのログインが必要です。参加者ログイン後に閲覧・ダウンロードできます。
» 参加者用ログイン